Author response for 'Effects of Once‐Weekly Subcutaneous Semaglutide on Coronary Artery Disease Outcomes in Patients with Type 2 Diabetes with or at High Risk for Cardiovascular Disease: Insights from the SUSTAIN‐6 Trial'

Authors :: null Ahmed A. Kolkailah
null Ildiko Lingvay
null Idit Dobrecky‐Mery
null Alona Aharonovich
null Jens‐Peter David
null Cecilie Holse
null Søren Rasmussen
null Darren K. McGuire
Publication Year :: 2022
Publisher :: Wiley, 2022.

Tools